199 related articles for article (PubMed ID: 37341071)
1. Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma.
Onda M; Ota A; Ito K; Ono T; Karnan S; Kato M; Kondo S; Furuhashi A; Hayashi T; Hosokawa Y; Kazaoka Y
Cancer Med; 2023 Aug; 12(15):16416-16430. PubMed ID: 37341071
[TBL] [Abstract][Full Text] [Related]
2. Curcumol Exerts Antitumor Effect via Inhibiting EGFR-Akt-Mcl-1 Signaling.
Li XY; Gao F; Wang XC; Liu LL; Gan Y; Han SZ; Zhou L; Li W; Li M
Am J Chin Med; 2023; 51(3):741-760. PubMed ID: 36869017
[TBL] [Abstract][Full Text] [Related]
3. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
4. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
Sasabe E; Tomomura A; Yamamoto T
J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
Cai Z; Hao XY; Liu FX
Arch Oral Biol; 2018 May; 89():20-25. PubMed ID: 29407635
[TBL] [Abstract][Full Text] [Related]
6. Carboxylesterase 2 induces mitochondrial dysfunction via disrupting lipid homeostasis in oral squamous cell carcinoma.
Chen X; Liu Q; Chen Y; Wang L; Yang R; Zhang W; Pan X; Zhang S; Chen C; Wu T; Xia J; Cheng B; Chen X; Ren X
Mol Metab; 2022 Nov; 65():101600. PubMed ID: 36113774
[TBL] [Abstract][Full Text] [Related]
7. The antitumor effects of herbal medicine Triphala on oral cancer by inactivating PI3K/Akt signaling pathway: based on the network pharmacology, molecular docking, in vitro and in vivo experimental validation.
Hu S; Li S; Xu Y; Huang X; Mai Z; Chen Y; Xiao H; Ning W; Gaus S; Savkovic V; Lethaus B; Zimmerer R; Acharya A; Ziebolz D; Schmalz G; Huang S; Zhao J; Hu X
Phytomedicine; 2024 Jun; 128():155488. PubMed ID: 38493718
[TBL] [Abstract][Full Text] [Related]
8. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
Wang Q; Zhang X; Song X; Zhang L
Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.
Smolensky D; Rathore K; Bourn J; Cekanova M
J Cell Biochem; 2017 Sep; 118(9):2615-2624. PubMed ID: 27649518
[TBL] [Abstract][Full Text] [Related]
11. As a Novel Tumor Suppressor, LHPP Promotes Apoptosis by Inhibiting the PI3K/AKT Signaling Pathway in Oral Squamous Cell Carcinoma.
Liu S; Gao W; Lu Y; Zhou Q; Su R; Hasegawa T; Du J; Li M
Int J Biol Sci; 2022; 18(2):491-506. PubMed ID: 35002505
[TBL] [Abstract][Full Text] [Related]
12. Potential targets of diosgenin for the treatment of oral squamous cell carcinoma and their bioinformatics and transcriptional profiling analyses.
Xiao Y; Xu B; Li X; Ding T; Zhao W; Nie X; Mu J; Xiao Z; Wang Q; Ren Q; Zhang E
Steroids; 2024 May; 205():109393. PubMed ID: 38458369
[TBL] [Abstract][Full Text] [Related]
13. Activin A regulates the epidermal growth factor receptor promoter by activating the PI3K/SP1 pathway in oral squamous cell carcinoma cells.
Tsai CN; Tsai CL; Yi JS; Kao HK; Huang Y; Wang CI; Lee YS; Chang KP
Sci Rep; 2019 Mar; 9(1):5197. PubMed ID: 30914776
[TBL] [Abstract][Full Text] [Related]
14. Membrane-tethered Notch1 exhibits oncogenic property via activation of EGFR-PI3K-AKT pathway in oral squamous cell carcinoma.
Zheng Y; Wang Z; Xiong X; Zhong Y; Zhang W; Dong Y; Li J; Zhu Z; Zhang W; Wu H; Gu W; Wu Y; Wang X; Song X
J Cell Physiol; 2019 May; 234(5):5940-5952. PubMed ID: 30515785
[TBL] [Abstract][Full Text] [Related]
15. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
16. Curcumin nanoemulsions inhibit oral squamous cell carcinoma cell proliferation by PI3K/Akt/mTOR suppression and miR-199a upregulation: A preliminary study.
Liu W; Wang J; Zhang C; Bao Z; Wu L
Oral Dis; 2023 Nov; 29(8):3183-3192. PubMed ID: 35689522
[TBL] [Abstract][Full Text] [Related]
17. FERMT1 knockdown inhibits oral squamous cell carcinoma cell epithelial-mesenchymal transition by inactivating the PI3K/AKT signaling pathway.
Wang X; Chen Q
BMC Oral Health; 2021 Nov; 21(1):598. PubMed ID: 34814915
[TBL] [Abstract][Full Text] [Related]
18. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
20.
Tang KL; Tang HY; Du Y; Tian T; Xiong SJ
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31213575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
